u/helga_vermeulen

This is correct. Private and NHS pathways are different.

This is correct. Triple agonism is genuinely different.

Boots stock check: called 3 locations in France, 5 had 0.25mg in stock. Regional variation is real.

the 2.4mg dose is not the target, it is just what the pen goes up to

Maintenance for 5 months now. Weight moves within about 3kg and the dose is a quarter of what it peaked at.

Every time this gets posted it hits the front page and every time someone has to re-explain it.

say which nation, England, Scotland, Wales, NI differ

tendon and CagriSema literature in rodents is interesting

This is correct. Discontinuation data is real.

NHS or private?

Yeah, the NHS waitlist is genuinely two years in most places.

I am going to push back on this slightly.

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

Small correction: the trial was 14 weeks, not 38. Does not change your point but people will quote it.

This is the "correlation is mechanism" thing again.

Yes, exactly this, and it is the bit that took me 73 weeks to accept.

You have restated the marketing copy. What is the actual substance here.

the co-agonism question is real and interesting

week 30 on the pen, 7kg down, this is the answer

MHRA supply notices change monthly, follow the actual list

Which country? Half the answers in this thread only apply in Spain.

private prescription routes vary by region